表紙:パーキンソン病治療薬:世界の市場および臨床試験の分析 (~2025年)
市場調査レポート
商品コード
922266

パーキンソン病治療薬:世界の市場および臨床試験の分析 (~2025年)

Global Parkinson's Drug Market & Clinical Trial Insight 2025

出版日: | 発行: PNS Pharma | ページ情報: 英文 500 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.03円

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

パーキンソン病治療薬:世界の市場および臨床試験の分析 (~2025年)
出版日: 2020年01月16日
発行: PNS Pharma
ページ情報: 英文 500 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

パーキンソン病治療薬市場は現在、急激な成長を目の当たりにしており、未開拓の可能性を秘めた巨大な治療薬市場セグメントとして浮上しています。パーキンソン病を管理するための新しいアプローチの開発に加え、多種多様な治療薬が存在していることは、パーキンソン病治療薬市場の明るい未来を示唆しています。同治療薬市場セグメントは、認知症、震え、硬直、緩慢な動作といったパーキンソン病のさまざまな症状に対して、治療薬のターゲティングメカニズムが多様であることから、製薬、バイオテクノロジー、ライフサイエンス企業に多くの機会と手段を提供しています。

当レポートでは、世界のパーキンソン病治療薬の上市済み製品および臨床パイプラインの動向を調査し、治療薬の開発の経緯、世界の有病率・統計、主な上市済み薬、薬剤クラス・フェーズ別の臨床パイプラインの動向、主要企業のプロファイルなどをまとめています。

第1章 世界におけるパーキンソン病の罹患率・統計

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • ロシア
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • ニュージーランド

第2章 世界のパーキンソン病治療薬市場の分析

  • 現在の市況
  • 世界のパーキンソン病治療薬市場のセグメンテーション

第3章 抗パーキンソン病薬:市場分析

  • レボドパ/カルビドパ治療薬
  • ドーパミン作用薬
  • モノアミン酸化酵素 B 阻害薬 (MAOB)
  • カテコール-O-メチルトランスフェラーゼ (COMT)
  • その他

第4章 世界のパーキンソン病治療薬市場:促進要因

第5章 世界のパーキンソン病治療薬市場:課題

第6章 世界のパーキンソン病治療薬市場:将来展望

第7章 世界のパーキンソン病治療薬:臨床パイプライン概要

  • フェーズ別
  • 薬剤クラス別
  • 機序別
  • 配合別
  • 国別

第8章 世界のパーキンソン病治療薬臨床試験:調査段階

  • 概要
  • 臨床パイプラインの分析

第9章 世界のパーキンソン病治療薬臨床試験:前臨床段階

第10章 世界のパーキンソン病治療薬臨床試験:臨床段階

第11章 世界のパーキンソン病治療薬臨床試験:第I相

第12章 世界のパーキンソン病治療薬臨床試験:第I/II相

第13章 世界のパーキンソン病治療薬臨床試験:第II相

第14章 世界のパーキンソン病治療薬臨床試験:第II/III相

第15章 世界のパーキンソン病治療薬臨床試験:第III相

第16章 世界のパーキンソン病治療薬臨床試験:申請済み

第17章 世界のパーキンソン病治療薬臨床試験:承認済み

第18章 世界のパーキンソン病治療薬臨床試験分析

第19章 競合環境

  • Novartis
  • Merck
  • Pfizer
  • GlaxoSmithKline
  • Roche
  • Teva Pharmaceuticals
  • AbbVie Inc.
  • Mylan
  • Boehringer Ingelheim
  • Orion Pharma
  • ACADIA Pharmaceuticals Inc
図表

List of Figures

  • Figure 1-1: Global - Patients with Parkinson's Disease (Million), 2016 & 2019
  • Figure 1-2: Global - Prevalence of Parkinson's Disease by Age, 2019
  • Figure 1-3: Global - Parkinson's Cases by Leading Countries (Million), 2019
  • Figure 1-4: Global - Parkinson's Cases by Leading Countries (%), 2019
  • Figure 1-5: Global - Parkinson's Prevalence by Gender (%), 2019
  • Figure 1-6: US - Number of Parkinson's Patients (Million), 2016, 2020 & 2030
  • Figure 1-7: US - Age Standardized Parkinson's Prevalence Rate (Per 100,000 Population), 2019
  • Figure 1-8: US - Parkinson's Patients by Leading States, 2019
  • Figure 1-9: US - Parkinson's Patients by Gender (Million), 2019
  • Figure 1-10: US - Total Population v/s Population with 65+ Age (Million), 2019
  • Figure 1-11: US - Number of Parkinson's Related Deaths & Incidence, 2017
  • Figure 1-12: US - Age Standardized Parkinson's Death Rate (Per 100,000 Peoples), 2017
  • Figure 1-13: Canada - Age Standardized Parkinson's Average Prevalence Rate (Per 100,000 Peoples), 2019
  • Figure 1-14: Canada - Parkinson's Patients by Gender, 2019
  • Figure 1-15: Canada - Parkinson's Disease Related Deaths, 2016 & 2017
  • Figure 1-16: Canada - Age Standardized Parkinson's Death Rate by Gender (Per 100,000 Peoples), 2017
  • Figure 1-17: Canada - Total Population vs Population with 65+ Age (Million), 2019
  • Figure 1-18: UK - Patients with Parkinson's Disease, 2015, 2018 & 2025
  • Figure 1-19: UK - Newly Diagnosed Cases of Parkinson's Disease, 2015, 2018 & 2025
  • Figure 1-20: UK - Parkinson's Patients by Countries, 2018
  • Figure 1-21: UK - Parkinson's Patients Share by Countries (%), 2018
  • Figure 1-22: UK - Newly Diagnosed Parkinson's Cases by Countries, 2018
  • Figure 1-23: UK - Parkinson's Patients by Age, 2018
  • Figure 1-24: UK - Total Population v/s Population with 65+ Age (Million), 2019
  • Figure 1-25: UK - Parkinson's Related Deaths, 2016 & 2017
  • Figure 1-26: UK - Age Standardized Parkinson's Death Rate (Per 100,000 Peoples), 2017
  • Figure 1-27: Germany - Parkinson's disease Patients, 2016 & 2019
  • Figure 1-28: Germany - Parkinson's Patients by Gender, 2019
  • Figure 1-29: Germany - Total Population v/s Population with 65+ Age (Million), 2019
  • Figure 1-30: Germany - Parkinson's related Deaths, 2016 & 2017
  • Figure 1-31: Germany - Age Standardized Parkinson's Death Rate by Gender, 2017
  • Figure 1-32: Russia - Parkinson's Affected Population, 2016 & 2019
  • Figure 1-33: Russia - Age Standardized Parkinson's Prevalence Rate (Per 100,000 Peoples), 2016
  • Figure 1-34: Russia - Age Standardized Parkinson's Death Rate (Per 100,000 Peoples), 2017
  • Figure 1-35: Russia - Total Population v/s Population with 65+ Age (Million), 2019
  • Figure 1-36: China - Parkinson's Patients (Million), 2016 & 2019
  • Figure 1-37: Global - Parkinson's Cases - China v/s ROW (%), 2019
  • Figure 1-38: China - Parkinson's Cases by Gender (Million), 2019
  • Figure 1-39: China - Average Age Standardized Parkinson's Prevalence & Incidence Rate (Per 100,000 Peoples), 2019
  • Figure 1-40: China - Age Standardized Parkinson's Death Rate (Per 100,000 Peoples), 2017
  • Figure 1-41: China - Total Population v/s Population over 65+ Age (Million), 2019
  • Figure 1-42: Japan - Average Age Standard Parkinson's Prevalence Rate (Per 100,000 Peoples), 2019
  • Figure 1-43: Japan - Average Age Standard Parkinson's Incidence Rate (Per 100,000 Peoples), 2019
  • Figure 1-44: Japan - Parkinson's Cases & Deaths, 2016
  • Figure 1-45: Japan - Parkinson's Related Deaths, 2016 & 2017
  • Figure 1-46: Japan - Age Standardized Parkinson's Death Rate (Per 100,000 Peoples), 2017
  • Figure 1-47: Japan - Total Population v/s Population over 65+ Age (Million), 2019
  • Figure 1-48: India - Age Standardized Parkinson's Prevalence & Incidence Rate (Per 100,000 Peoples), 2019
  • Figure 1-49: India - Parkinson's Affected Population, 2016 & 2019
  • Figure 1-50: India - Parkinson's related Deaths, 2016 & 2017
  • Figure 1-51: India - Age Standardized Parkinson's Death Rate by Gender (Per 100,000 Peoples), 2017
  • Figure 1-52: India - Total Population v/s Population over 65+ Age (Million), 2019
  • Figure 1-53: South Korea - Parkinson's Incidence & Deaths, 2016
  • Figure 1-54: South Korea - Parkinson's Related Deaths, 2016 & 2017
  • Figure 1-55: South Korea - Age Standardized Parkinson's Death Rate by Gender (Per 100,000 peoples), 2017
  • Figure 1-56: South Korea - Total Population v/s Population over 65+ Age (Million), 2019
  • Figure 1-57: Australia - Parkinson's Cases, 2016 & 2018
  • Figure 1-58: Australia - Age Standardized Parkinson's Prevalence Rate (Per 100,000 Peoples), 2019
  • Figure 1-59: Australia - Parkinson's Related Deaths, 2015, 2016 & 2017
  • Figure 1-60: Australia - Age Standardized Parkinson's Death Rate (Per 100,000 Peoples), 2017
  • Figure 1-61: Australia - Total Population v/s Population with 65+ Age (Million), 2019
  • Figure 1-62: New Zealand - Parkinson's Case, 2015, 2017, 2018 & 2022
  • Figure 1-63: New Zealand - Parkinson's Cases by Gender, 2017
  • Figure 1-64: New Zealand - Age Standardized Parkinson's Death Rate (Per 100,000 Peoples), 2017
  • Figure 1-65: New Zealand - Total Population v/s Population over 65+ Age (Million), 2019
  • Figure 2-1: Global - Parkinson's Drug Market Size (US$ Billion), 2016 - 2018
  • Figure 2-2: Global - Parkinson's Drug Market Size (US$ Billion), 2019 - 2025
  • Figure 2-3: Parkinson's Drug Market Size - Total v/s Europe (US$ Billion), 2019
  • Figure 2-4: Parkinson's Drug Market Share - ROW v/s Europe (%), 2019
  • Figure 2-5: Parkinson's Drug Market Size - Total v/s North America (US$ Billion), 2019
  • Figure 2-6: Parkinson's Drug Market Share - ROW v/s North America (%), 2019
  • Figure 2-7: Global - Parkinson's Drug Market Size by Mechanism (%), 2018
  • Figure 3-1: Duopa - FDA Approval & Patent Expiration Year
  • Figure 3-2: Duopa - Price of 700ml, 100ml & 1ml of Duopa 4.3-20mg/ml Suspension (US$), December'2019
  • Figure 3-3: Duopa - Maximum Daily, Monthly & Annual Treatment Cost for Parkinson's Treatment (US$), December'2019
  • Figure 3-4: Duopa - Global Sales Value (US$ Million), 2016, 2017 & 2018
  • Figure 3-5: Duopa - US Sales Value (US$ Million), 2016, 2017 & 2018
  • Figure 3-6: Duopa - Quarterly Sales Value (US$ Million), 2019
  • Figure 3-7: Rytray - Number of Patents Issued in Different Years
  • Figure 3-8: Rytray - Price for Supply of 240, 100 & Price per Unit of 23.75-95mg, 36.25-145 mg & 48.75-195mg Dose Capsules (US$), December'2019
  • Figure 3-9: Rytray - Price for Supply of 240, 100 & Price per Unit of 61.25-245mg Dose Capsules (US$), December'2019
  • Figure 3-10: Rytray - Recommended Initial & Incremented Dose for Treatment Parkinson's Patient Naïve to Levodopa Therapy, December'2019
  • Figure 3-11: Rytray - Global Sales Value (US$ Million), 2017 & 2018
  • Figure 3-12: Quarterly Sales Value (US$ Million), 2018 & 2019
  • Figure 3-13: Sinemet - Price of Different Dose Regimen of Sinemet Oral Tablet (US$), December'2019
  • Figure 3-14: Sinemet - Per Unit Price of Different Dose Regimen of Sinemet Oral Tablet (US$), December'2019
  • Figure 3-15: Sinemet - Recommended Initial & Maximum Dose (mg/day), December'2019
  • Figure 3-16: Sinemet - Per Day Treatment cost for Initial & Maximum Dose (US$), December'2019
  • Figure 3-17: Neupro - Different Patent Issue & Expiration Year
  • Figure 3-18; Neupro - Price for Supply of 30 Transdermal Films & Price per Unit (US$), December' 2019
  • Figure 3-19: Neupro - Initial & Maximum Recommended Dose for Early Stage Parkinson's (mg/day), December'2019
  • Figure 3-20: Neupro - Initial & Maximum Recommended Dose for Late Stage Parkinson's (mg/day), December'2019
  • Figure 3-21: Neupro - Global Sales (US$ Million), 2017 & 2018
  • Figure 3-22: Neupro - Global Half Yearly Sales Value (US$ Million), 2018 & 2019
  • Figure 3-23: Pramipexole - Price for 90 Tablets Supply of Different Doses (US$), December'2019
  • Figure 3-24: Pramipexole - Price for 90 Extended Release Tablets Supply of Different Doses (US$), December'2019
  • Figure 3-25: Pramipexole - Recommended Initial & Maintenance Dose Using Immideate Release Tablets (mg/day), December'2019
  • Figure 3-26: Pramipexole - Recommended Initial & Maintenance Dose Using Extended Release Tablets (mg/day), December'2019
  • Figure 3-27: Ropinirole - Price for 100 Tablet Supply of Different Doses (US$), December'2019
  • Figure 3-28: Ropinirole - Price for 500 Tablet Supply of Different Doses (US$), December'2019
  • Figure 3-29: Ropinirole - Price for 30 Extended Release Tablet Supply of Different Doses (US$), December'2019
  • Figure 3-30: Ropinirole - Weekly Recommended Dose & Maximum Dose of Immediate Release Tablet (mg Three Times a Day), December'2019
  • Figure 3-31: Ropinirole - Initial & Maximum Recommended Dose for Extended Release Tablet (mg/day), December'2019
  • Figure 3-32: Emsam - Price for 30 Patch Supply & Price per Unit of Various Doses of Emsam Transdermal Patches (US$), December'2019
  • Figure 3-33: Emsam - Monthly & Annual Treatment Cost of Parkinson's Disease (US$), December'2019
  • Figure 3-34: Selegiline - Price for 60 Capsule Supply & per Unit Price of 5mg Capsule (US$), December'2019
  • Figure 3-35: Selegiline - Price for 60 Tablet Supply & per Unit Price of 5mg Tablet (US$), December'2019
  • Figure 3-36: Selegiline - Annual Treatment Cost using Tablet & Capsule (US$), December'2019
  • Figure 3-37: Xadago - Patent Issue & Expiration Year
  • Figure 3-38: Xadago - Price for 30 Tablet Supply & Price per Unit (US$), December'2019
  • Figure 3-39: Xadago - Recommended Initial & Incremented Dose For Parkinson's Treatment (mg/day), December'2019
  • Figure 3-40: Generic Rasagiline - Price for 30 Tablet Supply of 0.5mg & 1mg Tablet (US$), December'2019
  • Figure 3-41: Azilect - Price for 30 Tablet Supply of 0.5mg & 1mg Tablet (US$), December'2019
  • Figure 3-42: Recommended Dose for Monotherapy & Adjuvant Therapy in Concomitant Levodopa/ NonLevodopa Patients (mg/day), December'2019
  • Figure 3-43: Generic Entacapone - Price for 30, 50 & 100 Tablet Supplies 200mg Tablet (US$), December'2019
  • Figure 3-44: Comtan - Price for 100 Tablet Supply & Price per Unit of 200mg Tablet (US$), December'2019
  • Figure 3-45: Entacapone - Recommended Initial & Maximum Dose (mg/day), December'2019
  • Figure 3-46 Entacapone - Treatment Cost per Day Using Generic & Branded Tablet (US$), December'2019
  • Figure 3-47: Generic Tolcapon - Price for 90 Tablet Supplies & Per Unit Price of 100mg Tablet (US$), December'2019
  • Figure 3-48: Tasmar - Price for 100 Tablet Supply & per Unit Price of 100mg Tablet (US$), December'2019
  • Figure 3-49: Tolcapone - Recommended Initial & Maximum Dose (mg/day), December'2019
  • Figure 3-50: Tolcapone - Treatment Cost per Day Using Generic & Branded Tablet (US$), December'2019
  • Figure 3-51: Generic Benztropine - Price for 10ml Supply & per Unit Price 1mg/ml Injectable Solution (US$), December'2019
  • Figure 3-52: Generic Benztropine - Price for 100 Tablet Supplies of 0.5mg, 1mg & 1.5mg Dose (US$), December'2019
  • Figure 3-53: Cogentin - Price for 10ml Supply & per Unit Price 1mg/ml Injectable Solution (US$), December'2019
  • Figure 3-54: Benztropine - Recommended Initial Dose & Maximum Dose (mg/day), December'2019
  • Figure 3-55: Amantidine - Price for 50 Capsules Supply & per Unit Price of 100mg Capsule (US$), December'2019
  • Figure 3-56: Amantidine - Price for 100 Tablets Supply & per Unit Price of 100mg Tablets (US$), December'2019
  • Figure 3-57: Amantidine - Price for 473ml, 1000ml Supplies & per Unit Price of 50mg/ml Syrup (US$), December'2019
  • Figure 3-58: Amantidine - Daily Treatment Cost using Syrup, Tablet & Capsules (US$), December'2019
  • Figure 3-59: Nourianz - Patent Issue & Expiration Year
  • Figure 3-60: Nourianz - Price for 90 Tablet Supply & Price per Unit of Oral Tablet (US$), December'2019
  • Figure 3-61: Nourianz - Recommended Initial & Maintenance Dose (mg/Day), December'2019
  • Figure 3-62: Nourianz - Maximum Daily, Monthly & Annual Treatment Cost (US$), December'2019
  • Figure 3-63: Exelon - Price for 30 Transdermal Patch Supply & Price per Unit (US$), December'2019
  • Figure 3-64: Generic Rivastigmine Transdermal Patch - Price for a Supply of 30 Patches of Dose 4.6mg, 9.5mg & 13.3 mg (US$), December'2019
  • Figure 3-65: Exelon - Initial & Maintenance Dose for the Treatment of Parkinson's Disease
  • Figure 3-66: Exelon - Monthly & Annual Treatment Cost for Treatment of Parkinson's disease
  • Figure 3-67: Rivastigmine - Price for a Supply of 60 capsules of Different Doses (US$), December'2019
  • Figure 3-68: Rivastigmine - Price for Single capsule of Different Doses (US$), December'2019
  • Figure 3-69: Rivastigmine - Recommended Initial, Maintenance & Incremented Maintenance Dose (mg/Day), December'2019
  • Figure 4-1: Global Parkinson's Drug Market Drivers
  • Figure 5 -1: Challenges for Global Parkinson's Drug Market
  • Figure 7-1: Global - Parkinson's Disease Clinical Pipeline by Phase (Number), 2020
  • Figure 7-2: Global - Parkinson's Drug Pipeline by Drug Class (Number), 2020 till 2025
  • Figure 7-3: Global - Parkinson's Drug Pipeline by Mechanism Of Action (Number), 2020 till 2025
  • Figure 7-4: Global - Parkinson's Drug Pipeline by Formulation (Number), 2020 till 2025
  • Figure 7-5: Global - Parkinson's Drug Pipeline country (Number), 2020 till 2025
  • Figure 8-1: Share of Research Phase in Overall Parkinson's Drug Clinical Pipeline (%)
  • Figure 9-1: Share of Preclinical Phase in Overall Parkinson's Drug Clinical Pipeline (%)
  • Figure 10-1: Share of Clinical Phase in Overall Parkinson's Drug Clinical Pipeline (%)
  • Figure 11-1: Share of Phase-I in Overall Parkinson's Drug Clinical Pipeline (%)
  • Figure 12-1: Share of Phase I/II in Overall Parkinson's Drug Clinical Pipeline (%)
  • Figure 13-1: Share of Phase-II in Overall Parkinson's Drug Clinical Pipeline (%)
  • Figure 14-1: Share of Phase- II/III in Overall Parkinson's Drug Clinical Pipeline (%)
  • Figure 15-1: Share of Phase-III in Overall Parkinson's Drug Clinical Pipeline (%)
  • Figure 16-1: Share of Preregistration Phase in Overall Parkinson's Drug Clinical Pipeline (%)
  • Figure 17-1: Share of Registered Phase in Overall Parkinson's Drug Clinical Pipeline (%)
目次

"Global Parkinson's Drug Market & Clinical Trial Insight 2025" Report Highlights:

  • Global Parkinson's Disease Prevalence & Statistics
  • Global Parkinson's Drug Market Opportunity: US$ 8 Billion
  • Parkinson's Drug Clinical Pipeline: >250 Drugs
  • Clinical Insight on Marketed Parkinson's Drug: 30 Drugs
  • Anti-Parkinson's Drugs - Availability, Dosage & Price Analysis
  • In-Depth Insight on More Than 250 Drugs In Clinical Trials

The parkinson's drug market is currently witnessing exponential growth and emerging as a huge therapeutic market segment with unexplored potential. Presence of a vast variety of therapeutics as well as development of new approaches for management of parkinson's disease is indicating towards a bright future of parkinson's drug market. This therapeutic market segment has open multiple opportunities and avenues for pharmaceutical, biotechnological and life science companies due to vast diversity in the targeting mechanism of drugs against the different symptoms of parkinson's such as dementia, tremor, rigidity and slow movements.

“The Parkinson's Drug Market Is Expected To Reach US$ 8 Billion By The Year 2025 Driven By Robust clinical Pipeline & Development Of New Therapeutic Drugs Class For More Effective And Safer Treatment Of Parkinson's Disease.”

The clinical pipeline of anti-parkinson's drug is very robust as more than 200 clinical trials are under investigation and several new drugs are about to get approved, that are different from the traditional anti-parkinson's drugs. The leading pharmaceutical companies are working for the development of new therapeutic drugs class for more effective and safer treatment of parkinson's disease. The investments related to parkinson's drug research and development is also increasing continuously and the subsequent approval of new anti-parkinson's drugs is expected in upcoming years. Currently, about 10 new drugs are in later stage of clinical development and are expected to get approval within next 3-4 years. The leading Pharmaceutical Players working in this segment are Novartis, GSK, Pfizer, Roche, UCB, etc.

Further, the intense research and development in parkinson's drug segment has led to discovery of many new compounds, which are currently showing prominent action in various phase of clinical trials. Many of the new anti-parkinson's drugs are expected to be a blockbuster products, once they come out of the clinical pipeline and are commercially available in the market. Currently, parkinson's disease is an untreatable complication and hence several research works are under investigation for the development of permanent cure of this disease. The leading pharmaceutical players are incorporating novel therapeutics such as monoclonal antibodies (Roche's PRX-002) and CRISPR gene editing technology, for developing effective and permanent treatment of Parkinson's disease. So, exponential growth in the market size of anti-parkinson's drug is expected in upcoming years.

The report “Global Parkinson Drug Market & Clinical Trial Insight 2025" provides a thoughtful insight about the market and also the various trends and the opportunities that are allied with the dynamics of the market growth. The key strategies adapted by the different market players are in a well-differentiated segment in the report. The research study provides both quantitative as well as qualitative assessment about the challenges faced by the market and the drivers leading to the growth of the market.

Table of Contents

1. Global Parkinson's Disease Prevalence & Statistics

  • 1.1. North America
    • 1.1.1. United States
    • 1.1.2. Canada
  • 1.2. Europe
    • 1.2.1. United Kingdom
    • 1.2.2. Germany
    • 1.2.3. Russia
  • 1.3. Asia- Pacific
    • 1.3.1. China
    • 1.3.2. Japan
    • 1.3.3. India
    • 1.3.4. South Korea
    • 1.3.5. Australia
    • 1.3.6. New Zealand

2. Global Parkinson's Drug Market Analysis

  • 2.1. Current Market Scenario
  • 2.2. Global Parkinson's Drug Market Segmentation
    • 2.2.1. Regional Segmentation
    • 2.2.2. Segmentation by Products

3. Anti-Parkinson's Drugs - Availability, Dosage & Price Analysis

  • 3.1. Levodopa/Carbidopa Therapeutics
    • 3.1.1. Duopa/Duodopa
    • 3.1.2. Rytary
    • 3.1.3. Sinemet
  • 3.2. Dopamine Agonist
    • 3.2.1. Rotigotine (Neupro)
    • 3.2.2. Pramipexole
    • 3.2.3. Ropinirole
  • 3.3. MAO B Inhibitors
    • 3.3.1. Selegiline
    • 3.3.2. Safinamide (Xadago)
    • 3.3.3. Rasagiline
  • 3.4. Catechol O-methyltransferase (COMT) inhibitors
    • 3.4.1. Entacapone
    • 3.4.2. Tolcapone
  • 3.5. Other Anti-Parkinson's Drugs
    • 3.5.1. Benztropine
    • 3.5.2. Amantidine
    • 3.5.3. Istradefylline (Nourianz)
    • 3.5.4. Rivastigmine

4. Global Parkinson's Drug Market Drivers

5. Challenges for Global Parkinson's Drug Market

6. Global Parkinson's Drug Market Future Outlook

7. Global Parkinson's Disease Drug Clinical Pipeline Overview

  • 7.1. By Phase
  • 7.2. By Drug Class
  • 7.3. By Mechanism of Action
  • 7.4. By Formulation
  • 7.5. By Country

8. Global Parkinson's Disease Drug Clinical Trial: Research Phase

  • 8.1. Overview
  • 8.2. Clinical Pipeline Insight

9. Global Parkinson's Disease Drug Clinical Trial: Preclinical Phase

  • 9.1. Overview
  • 9.2. Clinical Pipeline Insight

10. Global Parkinson's Disease Drug Clinical Trial: Clinical Phase

  • 10.1. Overview
  • 10.2. Clinical Pipeline Insight

11. Global Parkinson's Disease Drug Clinical Trial: Phase-I

  • 11.1. Overview
  • 11.2. Clinical Pipeline Insight

12. Global Parkinson's Disease Drug Clinical Trial: Phase-I/II

  • 12.1. Overview
  • 12.2. Clinical Pipeline Insight

13. Global Parkinson's Disease Drug Clinical Trial: Phase-II

  • 13.1. Overview
  • 13.2. Clinical Pipeline Insight

14. Global Parkinson's Disease Drug Clinical Trial: Phase-II/III

  • 14.1. Overview
  • 14.2. Clinical Pipeline Insight

15. Global Parkinson's Disease Drug Clinical Trial: Phase- III Phase

  • 15.1. Overview
  • 15.2. Clinical Pipeline Insight

16. Global Parkinson's Disease Drug Clinical Trial: Preregistration Phase

  • 16.1. Overview
  • 16.2. Clinical Pipeline Insight

17. Global Parkinson's Disease Drug Clinical Trial: Registered Phase

  • 17.1. Overview
  • 17.2. Clinical Pipeline Insight

18. Global Marketed Parkinson's Drugs Clinical Insight

19. Competitive Landscape

  • 19.1. Novartis
  • 19.2. Merck
  • 19.3. Pfizer
  • 19.4. GlaxoSmithKline plc
  • 19.5. Roche
  • 19.6. Teva Pharmaceuticals
  • 19.7. AbbVie Inc.
  • 19.8. Mylan
  • 19.9. Boehringer Ingelheim
  • 19.10. Orion Pharma
  • 19.11. ACADIA Pharmaceuticals Inc